Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | hydroxymethylglutaryl coenzyme A reductase | 0.3634 | 1 | 1 |
Schistosoma mansoni | hydroxymethylglutaryl-CoA reductase (NADPH) | 0.3634 | 1 | 1 |
Trichomonas vaginalis | 3-hydroxy-3-methylglutaryl-coenzyme A reductase, putative | 0.1705 | 0.3558 | 1 |
Mycobacterium ulcerans | hydroxymethylglutaryl-coenzyme a (HMG-CoA) reductase | 0.3634 | 1 | 0.5 |
Echinococcus multilocularis | Niemann Pick C1 protein | 0.1496 | 0.2861 | 0.2861 |
Leishmania major | 3-hydroxy-3-methylglutaryl-CoA reductase | 0.3634 | 1 | 0.5 |
Trichomonas vaginalis | 3-hydroxy-3-methylglutaryl-coenzyme A reductase, putative | 0.1705 | 0.3558 | 1 |
Giardia lamblia | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 0.1705 | 0.3558 | 0.5 |
Echinococcus granulosus | hydroxymethylglutaryl coenzyme A reductase | 0.3634 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.3634 | 1 | 1 |
Trypanosoma cruzi | 3-hydroxy-3-methylglutaryl-CoA reductase, putative | 0.3634 | 1 | 0.5 |
Trypanosoma brucei | 3-hydroxy-3-methylglutaryl-CoA reductase, putative | 0.3634 | 1 | 0.5 |
Echinococcus multilocularis | protein patched | 0.1496 | 0.2861 | 0.2861 |
Trichomonas vaginalis | 3-hydroxy-3-methylglutaryl-coenzyme A reductase, putative | 0.1705 | 0.3558 | 1 |
Echinococcus multilocularis | sterol regulatory element binding protein | 0.1496 | 0.2861 | 0.2861 |
Echinococcus multilocularis | protein dispatched 1 | 0.1496 | 0.2861 | 0.2861 |
Trypanosoma cruzi | 3-hydroxy-3-methylglutaryl-CoA reductase | 0.3634 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.5 uM | Concentration required to reduce proliferation of human breast adenocarcinoma (MCF-7) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.5 uM | Concentration required to reduce proliferation of human lung squamous carcinoma (SKMES-1) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.5 uM | Concentration required to reduce proliferation of human breast adenocarcinoma (MCF-7) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.5 uM | Concentration required to reduce proliferation of human lung squamous carcinoma (SKMES-1) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.7 uM | Concentration required to reduce proliferation of human acute B-lymphoblastic (CCRF-SB) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.7 uM | Concentration required to reduce proliferation of CD4+ human acute T-lymphoblastic leukemia (MT-4) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.7 uM | Concentration required to reduce proliferation of human acute B-lymphoblastic (CCRF-SB) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.7 uM | Concentration required to reduce proliferation of CD4+ human acute T-lymphoblastic leukemia (MT-4) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.8 uM | Concentration required to reduce proliferation of CD4+ human acuteT-lymphoblastic leukaemia (CCRF-CEM) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.8 uM | Concentration required to reduce proliferation of human breast adenocarcinoma (SKMEL-28) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.8 uM | Concentration required to reduce proliferation of CD4+ human acuteT-lymphoblastic leukaemia (CCRF-CEM) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.8 uM | Concentration required to reduce proliferation of human breast adenocarcinoma (SKMEL-28) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 0.9 uM | Concentration required to reduce proliferation of human foreskin fibroblasts (CRL-7065) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 1.5 uM | Concentration required to reduce proliferation of human prostate carcinoma (DU-145) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 1.5 uM | Concentration required to reduce proliferation of human prostate carcinoma (DU-145) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 2 uM | Concentration required to reduce proliferation of human splenic B-lymphoblastoid (Wil2-NS) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 2 uM | Concentration required to reduce proliferation of human hepatocellular carcinoma (HepG-2) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 2 uM | Concentration required to reduce proliferation of human splenic B-lymphoblastoid (Wil2-NS) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
IC50 (functional) | = 2 uM | Concentration required to reduce proliferation of human hepatocellular carcinoma (HepG-2) cell line by 50% as determined by the MTT method | ChEMBL. | 14761187 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 14761187 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.